This study investigates advanced solid tumors. It evaluates the safety and tolerability of an investigational medication called MDNA11, which is a long-acting "beta-only" recombinant interleukin-2.
The study focuses on evaluating the safety and effectiveness of MDNA11 alone or in combination with a checkpoint inhibitor. It looks at how well this investigational medication works and how the body responds to it.
- Who can participate: Participants must be at least 18 years old with an ECOG Performance Status of 0 to 1. They should have a confirmed diagnosis of advanced or metastatic solid tumors and a life expectancy of at least 12 weeks.
- Study details: Participants will receive MDNA11, either alone or with a checkpoint inhibitor.
How understandable was the trial content above?
Hard to understand
Easy to understand